Evidence map›Paper›PMID 39825204›Full record

ArticleEJNMMI radiopharmacy and chemistry2025

Evaluation of maSSS/maSES-PEG2-RM26 for their potential therapeutic use after labeling with Re-188. Could their [

Panagiotis Kanellopoulos, Quanyi Yu, Abouzayed Abouzayed, Ekaterina Bezverkhniaia, Vladimir Tolmachev, Anna Orlova

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI radiopharmacy and chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Panagiotis KanellopoulosDepartment of Medicinal Chemistry, Uppsala University, Uppsala, 751 23, Sweden. Panagiotis.kanellopoulos@ilk.uu.se.ORCID http://orcid.org/0000-0002-0617-3936
Quanyi YuDepartment of Medicinal Chemistry, Uppsala University, Uppsala, 751 23, Sweden.
Abouzayed AbouzayedDepartment of Medicinal Chemistry, Uppsala University, Uppsala, 751 23, Sweden.
Ekaterina BezverkhniaiaDepartment of Medicinal Chemistry, Uppsala University, Uppsala, 751 23, Sweden.
Vladimir TolmachevDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, 751 83, Sweden.
Anna OrlovaDepartment of Medicinal Chemistry, Uppsala University, Uppsala, 751 23, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGastrin releasing peptide receptor (GRPR)-directed radiopharmaceuticals for targeted radionuclide therapy may be a very promising addition in prostate and breast cancer patient management. Aiming to provide a GRPR-targeting theranostic pair, we have utilized the Tc-99m/Re-188 radiometal pair, in combination with two bombesin based antagonists, maSSS-PEG2-RM26 and maSES-PEG2-RM26. The two main aims of the current study were (i) to elucidate the influence of the radiometal-exchange on the biodistribution profile of the two peptides and (ii) to evaluate the feasibility of using the [

resultsBoth peptides were successfully labeled with Re-188 and evaluated both in vitro and in vivo. In GRPR expressing PC-3 cells, both [

conclusionsAll the results indicate that Tc-99 m could be used for dosimetry evaluation for the two [

Indexed as

AntagonistBombesinDosimetryEstimationGRPRPC-3Prostate cancerRadiopharmaceuticalsRe-188Tc-99m

Identifiers

PMID39825204
PMCPMC11748620

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.